secwatch.observer — SEC 8-K summary
======================================

Issuer:     IOVANCE BIOTHERAPEUTICS, INC. (IOVA)
CIK:        0001425205
Form:       8-K
Filed at:   2023-08-18T23:59:59+00:00
Accession:  0001104659-23-093553
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Iovance reports LN-145 + pembrolizumab 42.1% ORR in ICI-naïve mNSCLC trial
--------------------------------------------------------------------------

- ORR of 42.1% in ICI-naïve mNSCLC; 80% in treatment-naïve, 42.9% post-chemo, 14.3% EGFR-mutated post-TKI.
- Tumor burden reduction in 76.5% of patients; durable responses deepening over time up to 15.4 months.
- No new safety signals; TEAEs consistent with NMA-LD and IL-2 regimen.
- Results support phase 3 study design for LN-145 in front-line mNSCLC.
- Cash ~$478M (post-July offering) funds into end 2024; BLA filed for lifileucel in melanoma.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1425205/000110465923093553/0001104659-23-093553-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1425205/000110465923093553/tm2324118d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-093553

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer